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Summary.-Whilst the plasma CEA levels in pancreatic carcinoma tend to be higher
than in pancreatitis, knowledge of the plasma CEA level is of little additional value
in the differential diagnosis of malignant and non-malignant pancreatic disease, and
contributes little to the clinical management of such disorders.
THE STUDY REPORTED HERE is one of a
series initiated in 1973 by the Medical
Research Council and the Health Depart-
ment to investigate the diagnostic role of
the plasma carcinoembryonic antigen
(CEA) test. This study was designed to
assess whether the CEA test could help to
differentiate between patients with carci-
noma of the pancreas and those with
pancreatitis or gallstones. Other reports
tend to suggest that it has little to offer in
assisting with the initial or differential
diagnosis of neoplasms at certain site, e.g.
colon and rectum (Booth et al., 1974;
Laurence et al., 1972; Neville & Cooper,
1976; Zamcheck et al., 1975). The earlier
diagnosis of patients with pancreatic
carcinoma might improve the present poor
prognosis. It has been proposed that
plasma CEA assays are more often positive
than any other test for pancreatic cancer
(Freedman, 1978).
MATERIALS AND METHODS
Clinical and laboratory data.-Patients with
symptoms suggesting pancreatic disease were
entered into the study. Patients with pre-
viously confirmed pancreatic disease were
excluded. At an initial examination the fol-
lowing tests were made: (a) barium meal with
duodenal loop; (b) if no obstruction, i.v.
cholangiogram; (c) chest X-ray; (d) liver-
function tests (albumin/globulin, bilirubin,
SGOT, alkaline phosphatase, urea and elec-
trolytes); (e) full blood count and ESR; (f)
blood group (A, B, 0). A specimen of plasma
was taken and sent to the laboratory where
all the samples were estimated for CEA by
double-antibody radioimmunoassay (Laur-
ence et al., 1972). This method has a range of
values in normal subjects of up to 20 ng/ml;
in benign and inflammatory gastrointestinal
diseases, values up to 40 ng/ml may be
encountered (Laurence et al., 1972). A brief
history of the patient, together with the
results from the initial investigations, and
their interpretation in the form of a pre-
liminary diagnosis of pancreatitis, gallstones,
or carcinoma of the pancreas, were sent to
the MRC Statistical Research and Services
Unit. This preliminary diagnosis was qualified
as "definite", "probable" or "possible". The
plasma CEAresultwasalsosentindependently
to the MRC Unit, but not to the clinician in
charge of the patient.
Unless the diagnosis was "definite", the
patient was seen again at 3-monthly intervals
until a definite diagnosis could be made. At
each follow-up examination the relevant
diagnostic investigations were repeated and a
plasma specimen taken.
RESULTS AND i)ISCUSSION
A total of 1]10 patients were entered
from 4 different centres over a 2-year
period. Table I shows the initial plasma
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TABLE I.-The distribution ofinitialplasma (CEA valuesfor allpatients, in relation to the
diagnoses
Diagnosis at
initial
examination
Pancreatitis or
gallstones
Carcinoma of the
pancreas
Certainty
of
diagnosis
Definite
Probable
Possible
Definite
Probable
Possible
Initial plasma CEA (ng/ml)*
<10 10-19 20-39 40-99 > 100 Total
8
1
1
1
1
3
19
5
5
5
3
10
11
4
2
8
5
6
0
0
1
4
1
1
0
0
0
3
1
1
38
10
9
21
11
21
Total 15 47 36 7 5 110
* Normal- < 20 ng/ml. Benign and inflammatory conditions- < 40 ng/ml.
TABLE II.-Initial vsfinal diagnosis
Final diagnosis
Pancreatitis Carcinoma of
or gallstones the pancreas
Suspec- Suspec-
Definite ted Definite ted
Pancreatitis
Initial or gallstones
diagnosis Carcinoma of
the pancreas
Total
Definite
Suspected
Definite
Suspected
Other
disease
Non-
Malig- malig-
nant nant Total
36 0 0 0 2* 0 38
10 7 0 0 1 1 19
0 0 21 0 0 0 21
7 1 9 7 4 4 32
53 8 30 7 7 5 110
* One patient diagnosed as having gallstones, had at laparotomy, a bile-duct carcinoma. The other had
symptoms strongly suggesting pancreatitis, but at laparotomy, a small-cell tumour, thought to be lymphoma,
was found.
CEA values related to the diagnoses made
at the initial examination.
Statistical analyses (X2 test) show that
there is a significant difference between
the 2 distributions relating to definite
diagnoses, and that CEA values from
patients with carcinoma tend to be higher
than those from patients with pan-
creatitis or gallstones.
Establishment ofdiagnosis
Table II shows the relationship between
the initial and final diagnoses, i.e. made at
the last outpatient visit or immediately
preceding death. Such a diagnosis was not
always definite. The "probable" and
"possible" categories (Table I) have been
combined to form a single "suspected"
group.
Of the 19 patients suspected of pan-
creatitis or gallstones, 10 had this diag-
nosis confirmed; 7 remained "suspected".
Two were found to have other diseases;
one had chronic alcoholic liver disease
while the other had both carcinoma ofthe
gallbladder and a peptic ulcer. (The 7
patients whose diagnoses remained "sus-
pected" had symptoms indicative of
pancreatic disease resolving without treat-
ment before a definite diagnosis was made.
None was found to be suffering from
carcinoma of the pancreas.)
Of the 32 suspected of carcinoma of the
pancreas, 9 had this confirmed; 7 re-
mained in the "suspected" category; for 7
the diagnosis was changed to definite
pancreatitis or gallstones; and 8 had other
diseases; the diagnosis for the remaining
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TABLE III.-Initial plasma CEA level and interval before deflnite diagnosis, in patients
suspected of carcinoma of the pancreas
Definite diagnosis
Pancreatitis
or
gallstones
, -
Days Initial
to CEA
diagnosis (ng/ml)
1 13
11 21
120 17
123 8
164 11
193 6
215 1 1
7
Carcinoma
of the
pancreas
- A
Days
to
liagnosis
3
7
8
18
28
28
90
230
956
9
Initial
CEA
(ng/ml)
100
50
191
32
14
10
21
11
12
Othler
malignancy
Days Initial
to CEA
diagnosis (ng/ml)
7 17
7 82
461 26
unknown 36
Other
non-malignant
disease
Days Initial
to CEA
diagnosis (ng/ml)
2 23
14 14
23 33
379 9
4 4
patient was changed to suspected pan-
creatitis. Of the 8 patients with other
diseases, 4 were found to have non-
malignant disease (duodenal ulcer,
cirrhosis of the liver, drug-induced chole-
stasis and hepatic failure) and 4 were
found to have malignancy at other sites
(colon, stomach, ovary and liver).
It would seem, therefore, that if the
CEA test were able to differentiate
between carcinomas and pancreatites or
gallstones, in patients initially suspected
of carcinoma of the pancreas, the test
would be particularly useful. The data
from patients initially suspected of carcin-
oma of the pancreas, and for whom a
subsequent definite diagnosis has been
nade (on evidence other than CEA levels)
have been examined (Table III). Three of
the patients whose later diagnosis was
definite carcinoma of the pancreas had
very high initial plasma CEA levels
(> 50 ng/ml). However, these 3 cases were
all diagnosed within 8 days of their initial
examination, without knowledge of the
CEA results. The establishment of the
diagnosis for the remaining 6 took from
18 days to 21 years. One patient with
malignancy at another site was the only
other patient with a high plasma CEA
level (82 ng/ml); no patient with non-
malignant disease had an initial plasma
CEA level above 40 ng/ml.
Trend inplasma CEA values
A number of patients had 2 or more
plasma CEA values, representing initial
readings and subsequent follow-ups.
Changes in plasma CEA levels were ex-
amined in those patients to see whether
useful information could be gained from
follow-up readings.
The results indicate that changes in
plasma CEA levels were not particularly
useful diagnostically. The patients were
divided into 3 groups according to CEA
levels. Of the 42 patients with an initial
diagnosis of pancreatitis or gallstones (of
any degree of certainty) 36 were in the
"low" (< 20 ng/ml) group, 5 had "rising"
(20-39 ng/ml) CEA values and one was in
the "high" (> 40 ng/ml) group. Of the 39
patients with an initial diagnosis of
carcinoma of the pancreas, 18 had "low"
values, 7 had "rising" values and 14 were
in the "high" group. In the subgroup of
patients suspected of carcinoma of the
pancreas and for whom a definite diagnosis
was made, none of the 6 patients subse-
quently diagnosed as pancreatitis or gall-
stones fell into the "high" grouip, whereas
5/7 patients with carcinoma did.
Total patients
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In all the cases where a definite diag-
nosis of carcinoma was made, it was
reached within one month without know-
ledge ofany CEA results. In the remainder
ofthe cases, the trend to a high CEA level
took 4 months or longer to become appar-
ent. The patients tended to die within one
month of the high trend first becoming
established.
CONCLUSIONS
Whilst there was a strong positive
association between a diagnosis of definite
carcinoma and either raised plasma CEA
levels or rising trends in the CEA levels,
the detailed analyses carried out suggest
that for the patients in whom plasma CEA
assays might have helped, the diagnoses
were made fairly rapidly without recourse
to CEA. Its use in this aspect of onco-
logical differential diagnosis, therefore,
seems unwarranted. Several further bio-
chemical aids in the diagnosis of pan-
creatic cancer have been suggested (Banwo
et al., 1974; Hobbs et al., 1980; Wood et al.,
1976; Wood & Moosa, 1977). It will be
important to submit them to this type of
analytical and statistical approach iftheir
clinical value is to be assessed accurately.
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